[go: up one dir, main page]

ES2111700T3 - Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion. - Google Patents

Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion.

Info

Publication number
ES2111700T3
ES2111700T3 ES93119458T ES93119458T ES2111700T3 ES 2111700 T3 ES2111700 T3 ES 2111700T3 ES 93119458 T ES93119458 T ES 93119458T ES 93119458 T ES93119458 T ES 93119458T ES 2111700 T3 ES2111700 T3 ES 2111700T3
Authority
ES
Spain
Prior art keywords
cis
intermediaries
epoxides
usable
procedures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93119458T
Other languages
English (en)
Inventor
Sung Chun Kim
Nakyen Choy
Chang Sun Lee
Young Chan Son
Hoill Choi
Jong Sung Koh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
Lucky Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019920023089A external-priority patent/KR960000078B1/ko
Priority claimed from KR1019920023088A external-priority patent/KR960000077B1/ko
Priority claimed from KR1019930010811A external-priority patent/KR970011577B1/ko
Priority claimed from KR1019930021299A external-priority patent/KR960011580B1/ko
Priority claimed from KR1019930021298A external-priority patent/KR0125104B1/ko
Priority claimed from KR1019930021300A external-priority patent/KR0134497B1/ko
Application filed by Lucky Ltd filed Critical Lucky Ltd
Application granted granted Critical
Publication of ES2111700T3 publication Critical patent/ES2111700T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/36Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D303/00Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02Compounds containing oxirane rings
    • C07D303/38Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02Linear peptides containing at least one abnormal peptide link
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE CIS-EPOXIDOS REPRESENTADOS POR LA FORMULA (I-1), (I-2) O (I-3) QUE SON UTILES PARA EL TRATAMIENTO O PREVENCION DE ENFERMEDADES PROVOCADAS POR LA INFECCION POR EL VIH: EN DONDE: A, B, D, E, R1, R10, R11, K, G, Q, R Y J TIENE LOS SIGNIFICADOS DEFINIDOS EN LA ESPECIFICACION.
ES93119458T 1992-12-02 1993-12-02 Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion. Expired - Lifetime ES2111700T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR1019920023089A KR960000078B1 (ko) 1992-12-02 1992-12-02 인간 면역 결핍 바이러스 프로테아제의 억제 화합물 및 그의 제조방법
KR1019920023088A KR960000077B1 (ko) 1992-12-02 1992-12-02 인간 면역 결핍 바이러스 프로테아제의 억제 화합물 및 그의 제조방법
KR1019930010811A KR970011577B1 (ko) 1993-06-14 1993-06-14 항 에이즈(aids) 효과를 갖는 신규한 인간 면역 결핍 바이러스 프로테아제의 억제 화합물 및 그의 제조방법
KR1019930021299A KR960011580B1 (ko) 1993-10-14 1993-10-14 비가역적 에이치아이브이(hiv) 프로테아제 억제제의 중간체
KR1019930021298A KR0125104B1 (ko) 1993-10-14 1993-10-14 신규 인간 면역 결핍 바이러스(hiv) 프로테아제 억제 화합물 및 그의 제조방법
KR1019930021300A KR0134497B1 (ko) 1993-10-14 1993-10-14 비가역적 에이치아이브이 프로테아제 억제제

Publications (1)

Publication Number Publication Date
ES2111700T3 true ES2111700T3 (es) 1998-03-16

Family

ID=27555058

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93119458T Expired - Lifetime ES2111700T3 (es) 1992-12-02 1993-12-02 Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion.

Country Status (8)

Country Link
US (3) US5587388A (es)
EP (1) EP0601486B1 (es)
JP (2) JP2916359B2 (es)
AT (1) ATE159728T1 (es)
DE (1) DE69314911T2 (es)
DK (1) DK0601486T3 (es)
ES (1) ES2111700T3 (es)
GR (1) GR3025968T3 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2565745B2 (ja) * 1988-08-03 1996-12-18 新明和工業株式会社 垂直循環式駐車装置
US5587388A (en) * 1992-12-02 1996-12-24 Lucky Limited Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof
US5696134A (en) * 1993-11-30 1997-12-09 Lg Chemical Limited Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof
US5679687A (en) * 1993-11-30 1997-10-21 Lg Chemical Limited Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
EP0812857A1 (en) * 1994-12-08 1997-12-17 LG Chemical Limited Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
EP0812839A1 (en) * 1994-12-08 1997-12-17 LG Chemical Limited Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
US5670517A (en) * 1993-11-30 1997-09-23 Lg Chemical Limited Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
KR0125117B1 (ko) * 1994-06-15 1997-12-05 성재갑 항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법
KR0159652B1 (ko) * 1995-10-26 1998-12-01 성재갑 항 에이즈 효과를 갖는 비가역적 인간 면역 결핍 바이러스 프로테아제 저해제 및 그의 제조방법
DE19641691A1 (de) 1996-10-10 1998-04-16 Bayer Ag Substituierte 2-Amino-4-alkylamino-1,3,5-triazine
EP1365745A2 (en) 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP2328875B1 (en) * 2008-07-17 2014-10-15 University of Pittsburgh - Of the Commonwealth System of Higher Education Targeted nitroxide agents
GB201814067D0 (en) * 2018-08-29 2018-10-10 Univ Edinburgh Compounds for the inhibition of cyclophilins
WO2020175380A1 (ja) * 2019-02-26 2020-09-03 三菱瓦斯化学株式会社 アミン組成物、アミン化合物、製造方法およびその応用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
ES2077021T3 (es) * 1989-02-16 1995-11-16 Sankyo Co Peptidos que tienen actividad inhibidora de renina, su preparacion y uso.
US5114937A (en) * 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
EP0492136A3 (en) * 1990-12-20 1993-05-26 American Cyanamid Company Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene
US5268361A (en) * 1991-06-07 1993-12-07 Sri International Hydroxyazido derivatives and related compounds as renin inhibitors
US5587385A (en) * 1991-12-24 1996-12-24 Farmitalia Carlo Erba S.R.L. Arylidene-heterocyclic derivatives and process for their preparation
US5587388A (en) * 1992-12-02 1996-12-24 Lucky Limited Irreversible HIV protease inhibitors, intermediates, compositions and processes for the preparation thereof

Also Published As

Publication number Publication date
JPH072820A (ja) 1995-01-06
EP0601486B1 (en) 1997-10-29
JP2916359B2 (ja) 1999-07-05
DK0601486T3 (da) 1998-07-20
ATE159728T1 (de) 1997-11-15
US5744621A (en) 1998-04-28
US5763631A (en) 1998-06-09
DE69314911D1 (de) 1997-12-04
JPH1081653A (ja) 1998-03-31
GR3025968T3 (en) 1998-04-30
US5587388A (en) 1996-12-24
JP2978848B2 (ja) 1999-11-15
EP0601486A1 (en) 1994-06-15
DE69314911T2 (de) 1998-04-09

Similar Documents

Publication Publication Date Title
ES2111700T3 (es) Derivados de cis-epoxidos, utilizables como inhibidores irreversibles de la proteasa de hiv, y procedimientos e intermediarios para su preparacion.
ES2070660B1 (es) Un procedimiento para la preparacion de 2,5-damino-3-hidroxihexanos sustituidos, utiles como inhibidores de proteasas retrovirales.
NL300283I1 (nl) Alfa- en bèta-aminozuur-hydroxyethylamino-sulfonamiden die toepasbaar zijn als retrovirale-prothease-remmers.
DK260588D0 (da) Heterocykliske ketoner
NO304884B1 (no) 9-[(substituerte glycyl)amido]-6-demetyl-6-deoksotetracykliner, og medisinske preparater derav
DK0590428T3 (da) Azaquinoxaliner, fremgangsmåde til deres fremstilling og deres anvendelse
FI935778A (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
ATE269290T1 (de) Benzoylderivate
DE69820248D1 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
PT718293E (pt) Composto ciclodepsipeptidico
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
BR9305164A (pt) Composto, formulação farmacêutica e processo para preparar um composto
DK0587088T3 (da) Substituerede cyclohexan-derivater, fremgangsmåde til deres fremstilling og anvendelsen af forbindelserne til behandling af sygdomme
NZ228065A (en) 1,2,4-triazinediones and parasiticidal compositions; processes for preparation
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
FI952420A0 (fi) Glukopyranosidibentsotiofeenit
ATE88176T1 (de) 2-hydroxy-3-aryloxy-propylaminderivate mit kardiovaskulaerer wirkung.
DK0381114T3 (da) Exo-3,4-O-benzyliden-3"-demethylchartreusin og salte deraf
ES2068040T3 (es) Sales de 3-(cis-2,6-dimetilpiperidino)-sidnonimina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 601486

Country of ref document: ES